Molecular Staging of Cancer

1. Front Matter

   Pages I-XI

   PDF

2. Reviews

   1. Front Matter

      Pages 1-1

      PDF

   2. The Urokinase Receptor (uPAR, CD87) as a Target for Tumor Therapy: uPA-Silica Particles (SP-uPA) as a New Tool for Assessing Synthetic Peptides to interfere with uPA/uPA-Receptor Interaction

      • Elke Guthaus, Niko Schmiedeberg, Markus Bürgle, Viktor Magdolen, Horst Kessler, Manfred Schmitt

      Pages 3-14

   3. Molecular Regulation of Urokinase-Receptor Gene Expression as One Potential Concept for Molecular Staging and Therapy

      • Heike Allgayer

      Pages 15-30

   4. Stromal Cell Involvement in Cancer

      • Kasper Almholt, Morten Johnsen

      Pages 31-42

   5. Inhibition of the Tumor-Associated Urokinase-Type Plasminogen Activation System: Effects of High-Level Synthesis of Soluble Urokinase Receptor in Ovarian and Breast Cancer Cells in Vitro and in Vivo

      • Viktor Magdolen, Achim Krüger, Sumito Sato, Jutta Nagel, Stefan Sperl, Ute Reuning et al.

      Pages 43-63

   6. Molecular Mechanisms of Carcinogenesis in Gastric Cancer

      • Heinz Höfler, Karl-Friedrich Becker

      Pages 65-72

   7. Clinical Implications of Molecular Diagnosis in Hereditary Nonpolyposis Colorectal Cancer

      • Gabriela Möslein

      Pages 73-78

   8. Minimal Residual Disease in Gastric Cancer

      • Hendrik Seeliger, Hanno Spatz, Karl-Walter Jauch

      Pages 79-87

   9. Minimal Residual Disease in Breast Cancer and Gynecological Malignancies: Phenotype and Clinical Relevance

      • Frigga Roggel, Stefan Hocke, Kristina Lindemann, Sonja Sinz, Anita Welk, Martin Bosl et al.

      Pages 89-100

   10. Advanced Statistical Methods for the Definition of New Staging Models

       • Ronald Kates, Manfred Schmitt, Nadia Harbeck

       Pages 101-113

   11. Clinical Implications of the EGF Receptor/Ligand System for Tumor Progression and Survival in Gastrointestinal Carcinomas: Evidence for New Therapeutic Options

       • Reinhard Kopp, Elisabeth Rothbauer, Maximilian Ruge, Hans Arnholdt, Joachim Spranger, M. Muders et al.

       Pages 115-132

3. Original Papers

   1. Front Matter

      Pages 133-133

      PDF

   2. Minimal Residual Disease in Bone Marrow and Peripheral Blood of Patients with Metastatic Breast Cancer

      • Joachim Bischoff, Robert Rosenberg, Michael Dahm, Wolfgang Janni, Klaus Gutschow

      Pages 135-140

   3. Estrogen Receptor Expression Profile of Disseminated Epithelial Tumor Cells in Bone Marrow of Breast Cancer Patients

      • Nina Ditsch, Barbara Mayer, Michaela Rolle, Michael Untch, Friedrich Wilhelm Schildberg, Ilona Funke

      Pages 141-147

   4. Detection of Circulating Tumor Cells in Blood Using an Optimized Density Gradient Centrifugation

      • Ralf Gertler, Robert Rosenberg, Katrin Fuehrer, Michael Dahm, Hjalmar Nekarda, Joerg Ruediger Siewert

      Pages 149-155

   5. Antitumoral and Antimetastatic Effects of Continuous Particle-Mediated Cytokine Gene Therapy

      • Arne Dietrich, Katja Kraus, Ute Brinckmann, Christoph Stockmar, Anke Müller, Uwe Gerd Liebert et al.

      Pages 157-168

   6. Genetic Subtyping of Renal Cell Carcinoma by Comparative Genomic Hybridization

      • Kerstin Junker, Gregor Weirich, Mahul B. Amin, Petr Moravek, Winfried Hindermann, Joerg Schubert

      Pages 169-175

   7. Telomere Length and hTERT Expression in Patients with Colorectal Carcinoma

      • Robert Rosenberg, Ralf Gertler, Dominik Stricker, Silke Lassmann, Martin Werner, Hjalmar Nekarda et al.

      Pages 177-181

   8. Estimation of Concentration of Chosen Adhesive Factors in Suprarenal Tumours of “Incidentaloma” Type

      • Krzysztof Kołomecki, Henryk Stępień, Tomasz Stępień, Zbigniew Pasieka, Krzysztof Kuzdak

      Pages 183-188

An explosion of information has occurred since scientists began to define the molecular events that describe the malignant transformation and progression of cells and their development towards a life-threatening metastatic disease. The First International Congress on Molecular Staging of Cancer, held in Munich in December 2001, aimed to establish an international platform of exchange among molecular biologists, cell biologists, tumor immunologists, and clinical and surgical oncologists. This network approach should be fruitful for both clinicians and researchers. The highlighted topics included tumor-associated proteolysis, minimal residual disease, new approaches for molecular diagnosis and targeting, and the first molecular staging models. One session focused on technology transfer, opening up a new field of funding for innovative concepts. Finally, the impact of molecular staging on clinical strategies was discussed.

• Staging
• Telomere
• cancer
• carcinogenesis
• carcinoma
• cell
• cytokine
• gastric cancer
• gene expression
• gene therapy
• hybridization
• metastatic disease
• molecular mechanisms
• oncology
• tumor

• Dept. of Surgery, Klinikum Großhadern, Ludwig Maximilians Universität, München, Germany

  Heike Allgayer, Markus M. Heiss, Friedrich W. Schildberg

Policies and ethics